Delivery of Biologics to the Nasal Cavity Training Course

Dr. Julie D. Suman is the Vice President of Scientific Affairs for Aptar Pharma. She manages strategic scientific planning and Aptar’s Scientific Advisory Board. Dr. Suman is also the co-founder of Next Breath. She holds a B.S. in Pharmacy from Duquesne University (1996) and a Ph.D. in Pharmaceutical Sciences from the University of Maryland, Baltimore (2002). Dr. Suman serves on the External Advisory Committee of the New South Wales RNA Production and Research Network. In addition, she is a co-editor for Respiratory Drug Delivery Proceedings, an international symposium, and an Affiliate Assistant Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University. 

Dr Shur is an academic and entrepreneur having over 100 published scientific papers and was CEO of Nanopharm Ltd, which he led to a successful exit in 2019. Jag’s main area of research and commercial endeavour is in the complex topical pharmaceutical drug products area. A key theme of his research and commercial enterprises have been to develop patient-centric drug development platforms. He began his career with Profile Drug Delivery (now Philips Respironics) where he developed liquid dose drug delivery systems for cystic fibrosis patients, and later went on to work for GlaxoSmithKline. Jag holds a BSc (Hons) in Chemistry and completed his PhD, entitled ‘Formulated Muco-Regulatory Agents in the Airways of Patients with Cystic Fibrosis’. Following this, he was a post-doctoral fellow at the London School of Pharmacy, investigating the fabrication of microparticles for vaccine delivery using supercritical fluid technology.
Jag remains a part-time member of Nanopharm Ltd, an Aptar Pharma Company as Vice President of Science and Technology.

Irene Rossi is the Head of New Modalities Pharmaceutical Development at Nanopharm, an Aptar Company (UK). Irene obtained a MSc in Pharmaceutical Chemistry and Technology in 2014 and a PhD in Drugs, Biomolecules and Health Products at the Food and Drug Department, University of Parma (Italy) in 2019.
She joined Nanopharm in 2019 and she currently leads a group focused on the development of new technologies for OINDP products. Her main research area is the production, optimization and characterization of powders and liquid formulations for nasal and inhalation containing both small or large molecules. 
Up to date, Irene has submitted and published 6 original papers, a patent application on the development of a dry powder for pulmonary vaccination and she presented her work at more than 20 international conferences

Dr. Shields holds a Ph.D. in Biochemistry from the University of Pennsylvania and a B.S. in Chemical Engineering from the University of Michigan. He has 33 years of experience in process development and manufacturing of APIs and drug products, including recombinant peptide and protein production, formulation, sterile product manufacturing, oral solid dose, nasal sprays and nasal powders. He has built and operated pharmaceutical manufacturing facilities, and has overseen development and production of commercial drugs for both the US and European markets.